Literature DB >> 9476930

Tumor metabolic rates in sarcoma using FDG PET.

J F Eary1, D A Mankoff.   

Abstract

UNLABELLED: In a busy clinical environment, the arterial blood sampling and long imaging time used for the determination of tumor metabolic rates are not always feasible. In this study, the relationship of tumor standard uptake value (SUV) and metabolic rate of FDG (MRFDG) was investigated in a group of patients with sarcoma. To further investigate the implications of reducing blood sampling requirements for determining tumor metabolic rate, the relationship between FDG blood clearance, obtained from serial venous blood sampling and from a hybrid method of early cardiac blood pool imaging, and late venous blood sampling was analyzed.
METHODS: Comparisons of the sarcoma SUV and MRFDG obtained using graphical analysis, dynamic FDG imaging and venous blood sampling were made. Also, venous and hybrid blood time-activity curves were analyzed for similarity and for their effect on the estimated tumor metabolic rate.
RESULTS: For this group of patients with sarcoma (n = 42), the tumor SUV and MRFDG had a consistent relationship, with an overall correlation coefficient of 0.94. The MRFDG, determined by venous blood sampling, had a 6% average overestimate, compared to the same value obtained by the hybrid method of early blood pool imaging and late venous sampling.
CONCLUSION: Both the correlation of SUV and MRFDG and the hybrid blood pool/tumor imaging protocol provide clinically feasible methods for obtaining tumor metabolic rate information in a busy clinical PET service.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9476930

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  22 in total

1.  PET imaging in pediatric neuroradiology: current and future applications.

Authors:  Sunhee Kim; Noriko Salamon; Hollie A Jackson; Stefan Blüml; Ashok Panigrahy
Journal:  Pediatr Radiol       Date:  2009-11-24

2.  PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake.

Authors:  Lisa K Dunnwald; Robert K Doot; Jennifer M Specht; Julie R Gralow; Georgiana K Ellis; Robert B Livingston; Hannah M Linden; Vijayakrishna K Gadi; Brenda F Kurland; Erin K Schubert; Mark Muzi; David A Mankoff
Journal:  Clin Cancer Res       Date:  2011-03-01       Impact factor: 12.531

Review 3.  Preclinical PET tracers for the evaluation of sarcomas: understanding tumor biology.

Authors:  Ian R Sigal; Ronnie Sebro
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-12-20

4.  Near-simultaneous quantification of glucose uptake, mitochondrial membrane potential, and vascular parameters in murine flank tumors using quantitative diffuse reflectance and fluorescence spectroscopy.

Authors:  Caigang Zhu; Hannah L Martin; Brian T Crouch; Amy F Martinez; Martin Li; Gregory M Palmer; Mark W Dewhirst; Nimmi Ramanujam
Journal:  Biomed Opt Express       Date:  2018-06-27       Impact factor: 3.732

5.  Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1.

Authors:  R E Ferner; J D Lucas; M J O'Doherty; R A Hughes; M A Smith; B F Cronin; J Bingham
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-03       Impact factor: 10.154

6.  Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib.

Authors:  Bernd Kasper; Antonia Dimitrakopoulou-Strauss; Ludwig G Strauss; Peter Hohenberger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-06-19       Impact factor: 9.236

7.  Spatial heterogeneity in sarcoma 18F-FDG uptake as a predictor of patient outcome.

Authors:  Janet F Eary; Finbarr O'Sullivan; Janet O'Sullivan; Ernest U Conrad
Journal:  J Nucl Med       Date:  2008-11-07       Impact factor: 10.057

8.  Comparison of methodologies for the in vivo assessment of 18FLT utilisation in colorectal cancer.

Authors:  D Visvikis; D Francis; R Mulligan; D C Costa; I Croasdale; S K Luthra; I Taylor; P J Ell
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02       Impact factor: 9.236

9.  A review of controversies in the management of soft tissue sarcomas.

Authors:  S V S Deo; N M L Manjunath; N K Shukla
Journal:  Indian J Surg       Date:  2012-06-20       Impact factor: 0.656

10.  The use of positron emission tomography in soft tissue sarcoma patients under therapy with trabectedin.

Authors:  Bernd Kasper; Thomas Schmitt; Patrick Wuchter; Antonia Dimitrakopoulou-Strauss; Anthony D Ho; Gerlinde Egerer
Journal:  Mar Drugs       Date:  2009-07-17       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.